The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.
March 23rd 2024
The Princess of Wales is likely referencing adjuvant chemotherapy, but there is a growing field of immunoprevention, which seeks to target precancerous lesions or block heritable cancers.
Pembrolizumab Sustains Efficacy at 5 Years in First-Line, PD-L1+, Advanced NSCLC
July 15th 2023Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer (NSCLC).
Read More
At 5 Years, Data Affirm Durability of Axi-Cel Response in Refractory LBCL
June 22nd 2023Considering the depth and durability of responses with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL), the investigators added that CAR T cells should no longer be seen as a therapy only for heavily pretreated patients, but also as an option for earlier lines of therapy.
Read More
Study Finds Axi-Cel Benefits Older Patients With Relapsed or Refractory LBCL
June 17th 2023The findings, which suggest that axicabtagene ciloleucel (axi-cel) may be a good option for a patient group often deemed ineligible for other curative-intent therapy, come from a planned subgroup analysis from the ZUMA-7 trial.
Read More
Axi-Cel Shows Favorable Safety, Efficacy in Real-World Study of Early FL Outcomes
June 9th 2023The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).
Read More
Addressing Unmet Need: Could Children With Low-Grade Gliomas Have a New Treatment in Tovorafenib?
May 6th 2023For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.
Read More
Patients With Advanced Cancer With High TMB Show Favorable Outcomes on ICIs
May 5th 2023A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.
Read More
Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL Persist
April 13th 2023Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.
Read More
Early Recognition Key to Management of Immunotherapy Toxicities
April 11th 2023As much as immuno-oncology has been a leap forward, the ability to address immune-related adverse events is critical to making these therapies available in settings beyond academic centers; thus, the National Comprehensive Cancer Network offers clinical guidelines for management of toxicities.
Read More
DNA Sequencing Prior to HCT Identifies Patients at Risk of Poor AML Outcomes
April 8th 2023A study of patients with acute myeloid leukemia (AML) in first remission found that the presence of certain variants indicative of measurable residual disease ahead of allogeneic hematopoietic cell transplant (HCT) was associated with relapse and worse survival.
Read More
Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL
March 21st 2023A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).
Read More
Kentucky passes a bill to require insurers to cover biomarker tests for patients with cancer; CDC opioid guidelines updated in November may be too late for patients with chronic pain; the Environmental Protection Agency is proposing new limits to reduce dangerous human-manufactured chemicals in drinking water.
Read More
Lenvatinib Plus Pembrolizumab Shows Durable Efficacy Benefits vs Sunitinib in Renal Cell Carcinoma
March 8th 2023The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.
Read More
Dr Sashi Naidu: Partnering With Molecular Diagnostic Labs Facilitates Advanced Cancer Care
March 6th 2023Carolina Blood and Cancer Care Associates’ No One Left Alone initiative works to dismantle cancer health disparities and increase health care equity among its rural patient population. Sashi Naidu, MD, director of research, discusses delivering next-generation sequencing testing to patients.
Watch